Retinal vein occlusion
Retinal vein occlusion is the second commonest retinal vascular disease after diabetic retinopathy and a common cause of sudden painless visual loss in older adults. This lesson covers why central and branch veins block, how to tell an ischaemic from a non-ischaemic occlusion, the medical work-up, and the treatment of the two complications that take sight: macular oedema and new vessels.
Why retinal veins block
Venous blood leaves the retina through branch veins that join to form the central retinal vein, which exits through the optic nerve head. A thrombus can form at two kinds of site, and both are places where a vein is squeezed by its neighbouring artery.
In central retinal vein occlusion (CRVO) the block is at or just behind the lamina cribrosa, the sieve-like plate of sclera that the nerve fibres and central vessels pass through. Here the central retinal artery and vein lie side by side in a shared sheath in a rigid canal. A thickened, atherosclerotic artery compresses the vein, flow becomes turbulent, the endothelium is damaged and thrombus forms. This is Virchow's triad of vessel wall damage, stasis and hypercoagulability applied to the eye.
In branch retinal vein occlusion (BRVO) the block is at an arteriovenous crossing, where an arteriole and a venule share a common adventitial sheath. In almost every case the thick-walled artery lies in front of the thin-walled vein. The superotemporal quadrant is affected most often (around 60% of cases), probably because it has the most crossings. Nasal occlusions are seen least often.
3D atlasThe central retinal artery and vein share the narrow canal through the optic nerve head. Branch veins are compressed where arteries cross them.The risk factors follow from the mechanism. Most are the risk factors for arterial disease: increasing age (over 90% of CRVO occurs after 55), hypertension, hyperlipidaemia and smoking. Diabetes is usually listed too, although the Royal College of Ophthalmologists notes that it is no more common in these patients than in the general population. Raised intraocular pressure and glaucoma add risk by compressing the vein at the disc. Less often the cause is thick or sticky blood: myeloma and other hyperviscosity states, myeloproliferative disease, inflammatory disease such as Behcet disease and sarcoidosis, or oestrogen-containing contraception in younger women.
Central retinal vein occlusion
The patient notices painless blurring in one eye, often on waking. Blocked outflow raises venous and capillary pressure across the whole retina. The fundus shows dilated, tortuous veins, flame and blot haemorrhages in all four quadrants, cotton wool spots, a swollen optic disc and macular oedema. A florid case is described as a 'blood and thunder' fundus.
What matters next is how much capillary bed has closed. If back-pressure is high enough to stop arterial inflow, the retina infarcts. That is an ischaemic CRVO, and it behaves very differently from the commoner non-ischaemic type (about three quarters of cases at presentation).
| Non-ischaemic | Ischaemic | |
|---|---|---|
| Visual acuity | Usually 6/60 or better | Usually worse than 6/60 |
| Relative afferent pupillary defect | Absent or slight | Marked |
| Fundus | Milder haemorrhages, few cotton wool spots | Extensive deep haemorrhages, many cotton wool spots, severe disc swelling |
| Fluorescein angiography | Good capillary perfusion | Large areas of capillary non-perfusion (more than 10 disc areas in the Central Vein Occlusion Study) |
| Electroretinogram | Normal | Reduced b-wave |
| Risk of iris new vessels | Low unless it converts | About half of eyes, usually 2 to 4 months after onset |
| Visual outlook | About half recover normal or near-normal vision if it stays non-ischaemic | Poor |
A non-ischaemic occlusion can convert. In the Central Vein Occlusion Study about 15% converted within 4 months and about a third within 3 years, so the first few months need close follow-up.
Branch and hemiretinal occlusion
A BRVO gives the same signs as a CRVO but confined to a wedge of retina with its apex at the blocked crossing. Haemorrhages stop sharply at the horizontal midline, because superior and inferior venous drainage are separate. The patient may notice blurring, or a field defect in the opposite half of the visual field, or nothing at all if the macula is spared. A small macular BRVO affects only a venule draining the macula.
A hemiretinal vein occlusion involves the whole superior or inferior half of the retina. The haemorrhages are spread across two quadrants, above or below the horizontal midline.
Months later, collateral vessels may appear: tortuous channels that cross the horizontal midline or loop at the disc and bypass the blockage. They are helpful and should not be lasered. Unlike new vessels, collaterals do not leak on fluorescein angiography.
Without treatment roughly half of eyes with BRVO end with 6/12 or better. Those that do badly have persistent macular oedema, macular ischaemia or vitreous haemorrhage from new vessels.
Work-up
A vein occlusion is a sign of systemic vascular disease until shown otherwise, so the eye clinic looks for treatable causes. The Royal College of Ophthalmologists guideline (2022) recommends a short list for everyone.
- Medical history, including drugs.
- Blood pressure.
- Serum glucose, to find undiagnosed diabetes.
- Full blood count and erythrocyte sedimentation rate, which screen for hyperviscosity and inflammation.
Both eyes are also checked for raised intraocular pressure and glaucoma. Further tests are directed by the patient's doctor. Routine thrombophilia and antiphospholipid screening is not recommended for an isolated vein occlusion, because a positive result does not change management. Extra investigation is more often worthwhile in a patient under 50, in bilateral disease, or with a personal or family history of thrombosis. There is no good evidence that aspirin or anticoagulants help the eye.
In the eye, OCT measures macular oedema and tracks its response to treatment. Fluorescein angiography or OCT angiography maps capillary non-perfusion. Gonioscopy (examining the drainage angle with a contact lens) is done before dilating, because new vessels can appear in the angle before they are visible on the iris.
Macular oedema and its treatment
Macular oedema is the usual reason vision is reduced in a perfused eye. Ischaemic retina releases VEGF, capillaries leak, and fluid collects in cyst-like spaces at the fovea (cystoid macular oedema).
For both CRVO and BRVO the Royal College of Ophthalmologists recommends an intravitreal anti-VEGF drug or a dexamethasone implant. The choice is made with the patient, weighing the more frequent injections needed with anti-VEGF against the cataract and pressure rise caused by steroid. Anti-VEGF is given monthly until acuity is stable and then as needed. Treatment should start promptly in CRVO, because eyes treated after a delay of six months gain less.
In BRVO with recent, mild visual loss it is reasonable to watch for about three months, since some improve on their own. Macular grid laser was the standard treatment for BRVO oedema before anti-VEGF drugs, and it still has a small role when oedema has lasted three months, acuity is 6/12 or worse and the fovea is perfused. Grid laser does not improve vision in CRVO.
New vessels and neovascular glaucoma
The ischaemic retina in CRVO pours out VEGF, which diffuses forwards through the eye. New vessels on the retina itself are uncommon. They grow instead on the iris (rubeosis iridis) and in the drainage angle. A fibrovascular membrane then zips the angle shut and the pressure climbs. This neovascular glaucoma typically appears about three months after the occlusion, hence the old name '100-day glaucoma' (some texts say 90-day). It is painful and hard to treat.
Ischaemic eyes are therefore checked monthly for iris and angle new vessels for the first six months. At the first sign of them the eye is given anti-VEGF and panretinal photocoagulation. Prophylactic laser before new vessels appear is not routine when the patient can attend follow-up. Established neovascular glaucoma needs pressure-lowering drops, and sometimes cyclodiode laser or surgery.
BRVO behaves differently. The ischaemic sector lies next to perfused retina, so new vessels grow on the retina or disc, not the iris, and the danger is vitreous haemorrhage. Risk rises when more than about five disc diameters of retina is non-perfused. Treatment is sector laser to the ischaemic quadrant once new vessels appear.
Summary
- CRVO is thrombosis of the central vein at the lamina cribrosa; BRVO occurs at an arteriovenous crossing, most often superotemporally.
- The main risk factors are age, hypertension, hyperlipidaemia, smoking and raised intraocular pressure; hyperviscosity and inflammatory disease are rarer causes.
- CRVO gives haemorrhages in all four quadrants with dilated tortuous veins and disc swelling; BRVO gives a wedge of haemorrhage that respects the horizontal midline.
- Ischaemic CRVO is suggested by acuity worse than 6/60, a marked relative afferent pupillary defect and widespread capillary non-perfusion.
- About half of ischaemic CRVO eyes develop iris new vessels, usually within 2 to 4 months, leading to neovascular glaucoma.
- The RCOphth baseline work-up is history, blood pressure, glucose, full blood count and ESR; routine thrombophilia screening is not recommended.
- Macular oedema is treated with intravitreal anti-VEGF or a dexamethasone implant in both CRVO and BRVO.
- Iris or angle new vessels are treated with anti-VEGF and panretinal photocoagulation; retinal new vessels in BRVO are treated with sector laser.
- Collateral vessels are a late, harmless sign and do not leak on angiography.
Check yourself
Quick recall on this lesson. These are easier than the question bank.
Written for revision. It is not a source of clinical advice, and guidance changes.